Bionano Symposium 2026 continues with Day 2: New Frontiers in Oncology and Bioprocessing Applications on February 24, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...
Financial Conflicts of Interest: Payment at the Expense of Patients? In the article that accompanies this editorial, Weisse et al 11 present new findings about residential hospice care for patients ...
Hematological malignancies encompass a diverse range of diseases, such as leukemia, lymphoma, and multiple myeloma, among others. Within the multidisciplinary treatment approach, radiation therapy ...
In a recent study published in Life, researchers performed a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.
Ask the Experts - Hodgkin's Disease in the Larynx? What is the best way to treat a 29-year-old woman with a vocal cord mass? The mass is 2 x 1.5 cm; biopsy results are consistent with Hodgkin's ...
Tempering the 21st Century Cures Act: Physicians, Policy Advocacy, and Kentucky's Solution The following represents disclosure information provided by the author of this manuscript. All relationships ...
Long non-coding ribonucleic acids (lncRNAs), despite not coding for any protein, can play a significant role in cancer formation, progression, and treatment outcomes. One such lncRNA of interest is ...
The CAR T-cell therapy market is ripe for growth with over 250 companies and 500 drugs in development globally. Key opportunities lie in targeting hematologic malignancies and overcoming challenges in ...
Physical condition is the primary reason patients with blood cancers don’t receive treatment, followed by patient/family choice. In a new study, female patients were more likely than males to decline ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Patients with ...
Skysona will now only be indicated for patients without an available HLA-matched allogeneic hematopoietic stem cell donor. The Food and Drug Administration (FDA) has approved new safety labeling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results